BR0311965A - Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos - Google Patents
Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usosInfo
- Publication number
- BR0311965A BR0311965A BR0311965-3A BR0311965A BR0311965A BR 0311965 A BR0311965 A BR 0311965A BR 0311965 A BR0311965 A BR 0311965A BR 0311965 A BR0311965 A BR 0311965A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- adrenergic receptor
- alpha adrenergic
- formulations
- stabilized formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38620302P | 2002-06-20 | 2002-06-20 | |
US41104902P | 2002-09-17 | 2002-09-17 | |
US42115202P | 2002-10-24 | 2002-10-24 | |
US47392003P | 2003-05-29 | 2003-05-29 | |
PCT/US2003/019440 WO2004000219A2 (en) | 2002-06-20 | 2003-06-20 | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0311965A true BR0311965A (pt) | 2005-03-29 |
Family
ID=30003979
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0311965-3A BR0311965A (pt) | 2002-06-20 | 2003-06-20 | Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos |
BRPI0311965-3A BRPI0311965B1 (pt) | 2002-06-20 | 2003-06-20 | Formulação líquida estável e seu uso para aumentar fluxo sanguíneo em mamífero, método de preparação de forma de dosagem única de formulação líquida estável, bem como recipiente e kit |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0311965-3A BRPI0311965B1 (pt) | 2002-06-20 | 2003-06-20 | Formulação líquida estável e seu uso para aumentar fluxo sanguíneo em mamífero, método de preparação de forma de dosagem única de formulação líquida estável, bem como recipiente e kit |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1539170B1 (pt) |
JP (2) | JP4787977B2 (pt) |
AU (1) | AU2003247568B2 (pt) |
BR (2) | BR0311965A (pt) |
CA (1) | CA2489526C (pt) |
HK (1) | HK1079444A1 (pt) |
IL (1) | IL165599A (pt) |
MX (1) | MXPA04012507A (pt) |
NO (1) | NO20050300L (pt) |
WO (1) | WO2004000219A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2888699A1 (fr) | 2005-07-13 | 2007-01-19 | France Telecom | Dispositif de codage/decodage hierachique |
FR2897742A1 (fr) | 2006-02-17 | 2007-08-24 | France Telecom | Codage/decodage perfectionnes de signaux numeriques, en particulier en quantification vectorielle avec codes a permutation |
NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
ES2762153T3 (es) * | 2013-02-01 | 2020-05-22 | Ocuphire Pharma Inc | Soluciones oftálmicas acuosas de fentolamina y usos médicos de las mismas |
ES2835398T3 (es) * | 2013-02-01 | 2021-06-22 | Ocuphire Pharma Inc | Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual |
UY35988A (es) | 2014-02-27 | 2015-09-30 | Sint Sa | Proceso para la producción de una solución inyectable de noradrenalina de baja concentración |
WO2018140894A1 (en) | 2017-01-30 | 2018-08-02 | Nevakar, Inc | Norepinephrine compositions and methods therefor |
WO2020168213A1 (en) * | 2019-02-15 | 2020-08-20 | Massachusetts Institute Of Technology | Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659714A (en) * | 1984-03-27 | 1987-04-21 | Dentsply, Ltd. | Anesthetic methods for mammals |
US4938970A (en) | 1987-02-06 | 1990-07-03 | Hustead Robert E | Painless electrolyte solutions |
US5447912A (en) * | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
US6387052B1 (en) | 1991-01-29 | 2002-05-14 | Edwards Lifesciences Corporation | Thermodilution catheter having a safe, flexible heating element |
EP0691124A1 (en) | 1994-07-07 | 1996-01-10 | Sara Lee/DE N.V. | Mouth care products |
US6331291B1 (en) | 1996-05-30 | 2001-12-18 | William R. Glace | Dentifrice gel/paste compositions |
US5908612A (en) | 1996-12-31 | 1999-06-01 | Basf Corporation | Oral care compositions comprising liquid polyoxyalkylene compounds as solubilizers/gelling agents |
FR2768620B1 (fr) | 1997-09-22 | 2000-05-05 | Rhodia Chimie Sa | Formulation buccodentaire comprenant des nanofibrilles de cellulose essentiellement amorphes |
BR9815702B1 (pt) | 1998-03-06 | 2011-08-23 | composição de pasta de dente. | |
US6187293B1 (en) | 1998-04-27 | 2001-02-13 | Fmc Corporation | Process for making toothpaste using low levels of carrageenan |
US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
ATE352300T1 (de) * | 2000-05-12 | 2007-02-15 | Novalar Pharmaceuticals Inc | Zusammensetzung bestehend aus phentolaminmesylat und deren verwendung |
-
2003
- 2003-06-20 BR BR0311965-3A patent/BR0311965A/pt not_active IP Right Cessation
- 2003-06-20 AU AU2003247568A patent/AU2003247568B2/en not_active Ceased
- 2003-06-20 WO PCT/US2003/019440 patent/WO2004000219A2/en active Application Filing
- 2003-06-20 CA CA2489526A patent/CA2489526C/en not_active Expired - Lifetime
- 2003-06-20 MX MXPA04012507A patent/MXPA04012507A/es active IP Right Grant
- 2003-06-20 EP EP03761160.5A patent/EP1539170B1/en not_active Expired - Lifetime
- 2003-06-20 JP JP2004530955A patent/JP4787977B2/ja not_active Expired - Fee Related
- 2003-06-20 BR BRPI0311965-3A patent/BRPI0311965B1/pt unknown
-
2004
- 2004-12-07 IL IL165599A patent/IL165599A/en not_active IP Right Cessation
-
2005
- 2005-01-19 NO NO20050300A patent/NO20050300L/no not_active Application Discontinuation
- 2005-12-15 HK HK05111618.4A patent/HK1079444A1/xx not_active IP Right Cessation
-
2010
- 2010-08-11 JP JP2010180122A patent/JP2010280702A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1079444A1 (en) | 2006-04-07 |
EP1539170B1 (en) | 2014-08-13 |
AU2003247568A1 (en) | 2004-01-06 |
JP2005533869A (ja) | 2005-11-10 |
CA2489526C (en) | 2012-03-20 |
MXPA04012507A (es) | 2005-06-08 |
IL165599A (en) | 2015-01-29 |
NO20050300L (no) | 2005-03-04 |
IL165599A0 (en) | 2006-01-15 |
AU2003247568B2 (en) | 2008-03-06 |
WO2004000219A3 (en) | 2004-03-11 |
EP1539170A2 (en) | 2005-06-15 |
BRPI0311965B1 (pt) | 2018-04-24 |
CA2489526A1 (en) | 2003-12-31 |
JP4787977B2 (ja) | 2011-10-05 |
WO2004000219A2 (en) | 2003-12-31 |
EP1539170A4 (en) | 2011-01-05 |
JP2010280702A (ja) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
BR9509897A (pt) | Composição de liberação controlada para um material biologicamente ativo uso da mesma processo para preparação de uma composição de liberação controlada e para administração a mamíferos especialmente ao homem de um material biologicamante ativo e composição para uso como uma composição medicinal nasal | |
AR098830A2 (es) | Suspensiones acuosas estabilizadas para administración parenteral | |
BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
BR0016012A (pt) | Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração | |
BR0204001A (pt) | Forma de dosagem oral sólida de simeticona | |
AR012540A1 (es) | COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN | |
BR0111948A (pt) | Composição para entrega de fator de crescimento hematopoiético | |
FR2889811B1 (fr) | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. | |
BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
BR0311965A (pt) | Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos | |
BR0113539A (pt) | Processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia | |
AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
ES2173485T3 (es) | Anestesico local para uso externo. | |
AR064262A1 (es) | Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato | |
ECSP045349A (es) | Formuilaciones liquidas de baja dosis de entecavir y uso | |
BRPI9910024B8 (pt) | uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal | |
AR024232A1 (es) | Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
CL2002001701A1 (es) | Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. | |
BRPI0417001A (pt) | composto, composição farmacêutica, e, utilização de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/417, 31/505, 45/00, 47/04, 47/10, 47/12, 47/16, 47/18, 47/20, 47/22, 47/26, 47/34, 47/36, 9/08; A61P 1/02, 25/04, 37/06, 7/00 Ipc: A61K 31/417 (2011.01), A61K 31/505 (2011.01), A61K |
|
B25A | Requested transfer of rights approved |
Owner name: SEPTODONT HOLDING SAS (FR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/417 (2006.01), A61K 47/04 (2006.01), A61K |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2624 DE 20-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |